Tüdőrák: vizsgálatok itt: Németország
182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 16.. Ask the study team whether a trial fits you.
- 1/2. fázisNot yet taking people in NémetországA Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
- Where
- Dresden, Essen, Tuebingen
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00 - 1. fázisFut, nem toborozSTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Where
- Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
- Életkor
- 18 év and over
- People
- 15 worldwide
- Run by
- Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00 - 3. fázisTaking peopleA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Berlin, Bonn, Chemnitz, Dortmund, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Hannover, Herne, Kempten (Allgau), Luebeck, Marburg, Muenster, Munich, Ulm
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - 3. fázisTaking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Eschweiler, Giessen, Heidelberg, Kempten (Allgau), Mainz, Muenster, Oldenburg, Stuttgart
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - No phaseNot yet taking people in NémetországGeneral Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
- Where
- Frankfurt am Main
- Életkor
- 18 év and over
- People
- 306 worldwide
- Run by
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06950515 - 1/2. fázisTaking peopleA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Where
- Cologne, Jena, Tuebingen, Wuerzburg
- Életkor
- 18 év to 64 év
- People
- 170 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00 - 2. fázisTaking peopleBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Where
- Cologne, Heidelberg
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00 - 3. fázisTaking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Berlin, Bochum, Essen, Gera, Grosshansdorf, Heidelberg, Mainz, Regensburg
- Életkor
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Berlin, Bielefeld, Essen, Esslingen am Neckar, Gauting, Homburg, Offenbach Am Main, Oldenburg, Regensburg, Stuttgart, Wuerzburg
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - 3. fázisNot yet taking people in NémetországA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Where
- Berlin, Brunswick, Cologne, Dresden, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Homburg, Jena, Oldenburg, Stuttgart
- Életkor
- 18 év and over
- People
- 356 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00 - 1/2. fázisTaking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
- Életkor
- 12 év and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - 3. fázisFut, nem toborozStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Giessen, Goettingen, Heidelberg, Immenhausen, Köln, Luebeck, Munich
- Életkor
- 18 év and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg, Hanover, Heidelberg, Homburg, Immenhausen, Karlsruhe, Löwenstein, Lübeck, Mannheim, München, Münster, Oldenburg, Regensburg, Tübingen, Würzburg
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06793215 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Bad Berka, Berlin, Bonn, Essen, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Heidelberg, Homburg, Hösbach, Immenhausen, Jena, Kassel, Koblenz, Luebeck, Moers, Stuttgart
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00 - 3. fázisTaking peopleA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Augsburg, Berlin, Gauting, Goettingen, Grosshansdorf, Halle (saale), Immenhausen, Jena, Koblenz, Ludwigshafen Am Rhein, Luebeck, Regensburg
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00 - 1/2. fázisNot yet taking people in NémetországA Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
- Where
- Cologne, Essen, Frankfurt Am Main, Heidelberg, Oldenburg
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00 - 3. fázisTaking peopleA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Gera, Grosshansdorf, Halle (Saale), Hamburg, Heidelberg, Kiel, Muenster, Nuremberg, Tuebingen
- Életkor
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00 - 3. fázisFut, nem toborozA Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Berlin, Cologne, Essen, Frankfurt Am Main, Giessen, Hemer, Nuremberg, Stuttgart
- Életkor
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00 - 3. fázisTaking peopleStudy of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle, Hamburg, Heidelberg, Hemer, Herne, Leipzig, Nuremberg, Stuttgart, Tübingen
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00 - 2. fázisTaking peopleA Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Where
- Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
- Életkor
- 18 év and over
- People
- 254 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07492680 - 3. fázisFut, nem toborozA Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
- Where
- Berlin, Gauting, Georgsmarienhuette, Heidelberg, Mainz, Oldenburg
- Életkor
- 18 év and over
- People
- 65 worldwide
- Run by
- Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 - 2. fázisTaking peopleA Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Where
- Cologne, Grosshansdorf, Immenhausen, Wuerzburg
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Berlin, Gera, Grosshansdorf, Hanover, Mainz, Marburg, Moers, Muenster, Munich, Ravensburg
- Életkor
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - 1/2. fázisTaking peopleFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Where
- Berlin, Cologne, Dresden, Heidelberg
- Életkor
- 18 év and over
- People
- 334 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01 - 2. fázisTaking peopleA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Greifswald, Leipzig, Munich, Stuttgart
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00